<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01624870</url>
  </required_header>
  <id_info>
    <org_study_id>Advance-II</org_study_id>
    <nct_id>NCT01624870</nct_id>
  </id_info>
  <brief_title>CoreValve Advance-II Study: Prospective International Post-market Study</brief_title>
  <acronym>Advance-II</acronym>
  <official_title>CoreValve Advance-II Study: Best Practices Investigation of Patients Implanted With the Medtronic CoreValve Bioprosthesis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CoreValve ADVANCE-II Study is a best practices investigation of patients implanted with
      the Medtronic CoreValve bioprosthesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CoreValve ADVANCE-II Study is a best practices investigation of patients implanted with
      the Medtronic CoreValve bioprosthesis. The purpose of the study is to characterize best
      practices for CoreValve implantation in an effort to evolve implantation guidelines.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of new-onset class I or II indication for Permanent Pacemaker Implantation</measure>
    <time_frame>30 days post procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined safety endpoint</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>the combined safety endpoint is defined as a composite rate of:
all cause mortality
major stroke
Life threatening (or disabling) bleeding
Acute Kidney Injury - Stage 3 (including renale denervation therapy)
Peri-Procedural MI
Repeat procedure for valve-related dysfunction (surgical or interventional therapy)</description>
  </secondary_outcome>
  <enrollment type="Actual">200</enrollment>
  <condition>Aortic Valve Stenonis</condition>
  <condition>Valvular Heart Disease</condition>
  <condition>Transcatheter Aortic Valve Implantation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with aortic stenosis and at elevated surgical risk are eligible to be included in
        the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfilling the criteria of labeling indications of the CoreValve System;

          -  Patient is above the minimum age as required by local regulations to be participating
             in a clinical trial regardless of gender and race;

          -  Provided Signed Informed Consent or Data Release Form.

        Exclusion Criteria:

          -  Patients with a device regulating the heart rhythm by pacing (e.g. pacemaker,
             resynchronization device, implanted defibrillator);

          -  Patients with a pre-existing class I or class II indication for new pacemaker
             implantation according to the 2007 ESC guidelines;

          -  Persistent or permanent atrial fibrillation (except paroxysmal AF);

          -  Participation in another drug or device study that would jeopardize the appropriate
             analysis of endpoints of this study.

          -  High probability of non-adherence to the follow-up requirements (due to social,
             psychological or medical reasons)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Sonia Petronio, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero, Universitaria Pisana</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Podlesi Trinec</name>
      <address>
        <city>Trinec</city>
        <zip>73961</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite, Campus Mitte - Kardiologie Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico S. Ambrogio</name>
      <address>
        <city>Milan</city>
        <zip>20149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital Leicester</name>
      <address>
        <city>Leicester</city>
        <zip>Le3 9 QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2012</study_first_submitted>
  <study_first_submitted_qc>June 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2012</study_first_posted>
  <last_update_submitted>October 26, 2015</last_update_submitted>
  <last_update_submitted_qc>October 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Valve Stenonis</keyword>
  <keyword>Valvular Heart Disease</keyword>
  <keyword>Transcatheter Aortic Valve Implantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>September 6, 2016</submitted>
    <returned>October 26, 2016</returned>
    <submitted>October 27, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

